Effect of resveratrol trinicotinate versus resveratrol against tumors in vitro and in vivo

FAN Hui-ting,XIONG Xiao-yun,CAO Wei,LI Xiao-qiang,ZOU Yong,ZHANG Xue-jing,MEI Qi-bing
DOI: https://doi.org/10.3321/j.issn:1003-3734.2006.11.010
2006-01-01
Abstract:Objective: To compare antitumor effect and immunity of resveratrol versus prodrug resveratrol trinicotinate. Methods: MTT assay was used to examine inhibitions of resveratrol and resveratrol trinicotinate on growth of Hela, HepG2 and A549 cells. The models of mice S180 sarcoma and mice transplanted tumor H22 were used to test the antitumor effect in vivo. Thymus exponent, spleen exponent, leukocute number were applied to monitor the inhibition of mice immune organs. Results: The IC50 of resveratrol trinicotinate and resveratrol on Hela, HepG2 and A549 cells was 12.4×10-5 vs. 6. 3×10-5,9. 0×10-5 vs. 5.4×10-5 and 14. 6×10-5 vs. 7. 8×10-5 mol·L-1, respectively. At the dose of 25, 50 and 100 mg·kg-1, the average tumor inhibitory rates of resveratrol and resveratrol trinicotinate to mice S180 were 30.6%, 41.4% and 54.8% versus 38.1%, 49.4% and 62.2%, respectively (P 0. 01) ; the average tumor inhibitory rates to mice tumor H22 were 30. 1% , 38. 3% and 50. 2% versus 35. 9% , 45. 5% and 56. 6% , respectively (P 0. 01). No inhibition on immunological functions was found. Conclusion: Prodrug resveratrol trinicotinate remains the cytotoxicity of parent drug resveratrol in vitro, and also shows stronger antitumor effects than parent drug resveratrol in vivo.
What problem does this paper attempt to address?